.World Health And Wellness Organization. Being overweight as well as obese. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight (2024 ).
Non-Communicable Condition Threat Element Partnership. Worldwide trends in undersized and obesity from 1990 to 2022: a pooled evaluation of 3663 population-representative studies with 222 thousand children, adolescents, and grownups. Lancet 403, 1027u00e2 $ “1050 (2024 ).
Articleu00c2.Google.com Scholaru00c2.Global Problem Illness Partners. Global, regional, and also nationwide concern of diabetes mellitus coming from 1990 to 2021, with projections of incidence to 2050: a step-by-step evaluation for the Global Trouble of Ailment Study 2021. Lancet 402, 203u00e2 $ “234 (2023 ).
Articleu00c2.Google Scholaru00c2.Kovesdy, C. P., Furth, S. L.
& Zoccali, C & World Kidney Time Steering Board. Being overweight and kidney illness: hidden effects of the wide-ranging. Renal Int.
91, 260u00e2 $ “262 (2017 ). Garofalo, C. et cetera.
A methodical customer review and also meta-analysis recommends weight problems anticipates beginning of severe renal disease in the overall populace. Renal Int. 91, 1224u00e2 $ “1235 (2017 ).
Articleu00c2.Google Scholaru00c2.Jiang, Z. et al. Obesity and persistent renal disease.
Am. J. Physiol.
Endocrinol. Metab. 324, E24u00e2 $ “E41 (2023 ).
Articleu00c2.CASu00c2.Google.com Scholaru00c2.Hall, J. E., perform Carmo, J. M., da Silva, A.
A., Wang, Z. & Venue, M. E.
Obesity, kidney dysfunction as well as hypertension: mechanistic hyperlinks. Nat. Rev.
Nephrol. 15, 367u00e2 $ “385 (2019 ). Articleu00c2.PubMed Centralu00c2.Google Scholaru00c2.Kidney Ailment: Improving Worldwide End Results CKD Workplace Group.
KDIGO 2024 Clinical Method Tip for the examination as well as monitoring of chronic kidney disease. Renal Int. 105, S117u00e2 $ “S314 (2024 ).
Articleu00c2.Google Scholaru00c2.Renal Health Condition: Improving Global Results Diabetes Work Group. KDIGO 2022 Clinical Practice Tip for diabetes control in chronic renal health condition. Renal Int.
102, S1u00e2 $ “S127 (2022 ). Articleu00c2.Google Scholaru00c2.Oshima, M. et cetera.
Very early modification in albuminuria along with canagliflozin forecasts renal and also cardiovascular results: an article hoc study coming from the CREDENCE trial. J. Am.
Soc. Nephrol. 31, 2925u00e2 $ “2936 (2020 ).
Articleu00c2.CASu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.de Zeeuw, D. et al. Proteinuria, an intended for renoprotection in clients with kind 2 diabetic nephropathy: trainings from RENAAL.
Renal Int. 65, 2309u00e2 $ “2320 (2004 ). Articleu00c2.Google Scholaru00c2.Heerspink, H.
J. et cetera. Is a decline in albuminuria connected with renal as well as cardiovascular security?
An article hoc review of the ALTITUDE trial. Diabetes Obes. Metab.
18, 169u00e2 $ “177 (2016 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.Michos, E. D., Bakris, G.
L., Rodbard, H. W. & Tuttle, K.
R. Glucagon-like peptide-1 receptor agonists in diabetic renal health condition: a testimonial of their kidney and heart security. Are actually.
J. Prev. Cardiol.
14, 100502 (2023 ). Articleu00c2.PubMed Centralu00c2.Google Scholaru00c2.Muskiet, M. H.
A. et al. GLP-1 and the kidney: coming from physiology to pharmacology and end results in diabetic issues.
Nat. Rev. Nephrol.
13, 605u00e2 $ “628 (2017 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Marso, S. P.
et al. Semaglutide and heart end results in individuals along with style 2 diabetic issues. N.
Engl. J. Medication.
375, 1834u00e2 $ “1844 (2016 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Lincoff, A. M.
et al. Semaglutide and heart results in excessive weight without diabetes mellitus. N.
Engl. J. Med.
389, 2221u00e2 $ “2232 (2023 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Perkovic, V. et cetera.
Results of semaglutide on persistent renal ailment in patients with style 2 diabetes mellitus. N. Engl.
J. Medication. 391, 109u00e2 $ “121 (2024 ).
Articleu00c2.CASu00c2.Google.com Scholaru00c2.Colhoun, H. M. et al.
Long-lasting renal end results of semaglutide in excessive weight as well as heart disease in the SELECT test. Nat. Medication.
30, 2058u00e2 $ “2066 (2024 ). Articleu00c2.CASu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.Heerspink, H. J.
L. et al. Impacts of semaglutide on albuminuria as well as kidney function in folks along with overweight or obesity with or without kind 2 diabetic issues: exploratory review from the STEP 1, 2, as well as 3 trials.
Diabetic issues Treatment 46, 801u00e2 $ “810 (2023 ). Articleu00c2.CASu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.Medicine Man, A. M.
et cetera. Impact of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on renal outcomes in individuals along with style 2 diabetic issues: pooled study of SUSTAIN 6 and LEADER. Blood circulation 145, 575u00e2 $ “585 (2022 ).
Articleu00c2.CASu00c2.Google Scholaru00c2.Apperloo, E. M. et al.
Effect of semaglutide on kidney feature across different levels of baseline HbA1c, high blood pressure, physical body weight as well as albuminuria in SUSTAIN 6 and also PIONEER 6. Nephrol. Dial.
Transplant. gfae150 (2024 ). Tuttle, K.
R. et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes as well as moderate-to-severe persistent kidney illness (AWARD-7): a multicentre, open-label, randomised test.
Lancet Diabetes Mellitus Endocrinol. 6, 605u00e2 $ “617 (2018 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.Heerspink, H.
J. L. et cetera.
Change in albuminuria as a surrogate endpoint for advancement of kidney disease: a meta-analysis of procedure impacts in randomised scientific trials. Lancet Diabetes Endocrinol. 7, 128u00e2 $ “139 (2019 ).
Articleu00c2.CASu00c2.Google.com Scholaru00c2.Mann, J. F. E.
et cetera. Impacts of semaglutide with and without concomitant SGLT2 inhibitor make use of in attendees with type 2 diabetic issues as well as chronic kidney health condition in the circulation trial. Nat.
Medication. https://doi.org/10.1038/s41591-024-03133-0 (2024 ). Neuen, B.
L. et cetera. Cardiovascular, kidney and security outcomes with GLP-1 receptor agonists alone as well as in combo with SGLT2 preventions in kind 2 diabetes mellitus: a systematic testimonial and also meta-analysis.
Circulation https://doi.org/10.1161/CIRCULATIONAHA.124.071689 (2024 ). Apperloo, E. M.
et cetera. Effectiveness as well as protection of SGLT2 inhibitors along with and without glucagon-like peptide 1 receptor agonists: a SMART-C collective meta-analysis of randomised regulated trials. Lancet Diabetes Endocrinol.
12, 545u00e2 $ “557 (2024 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.Heerspink, H. J.
L. et al. Impacts of tirzepatide versus blood insulin glargine on renal outcomes in style 2 diabetic issues in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, stage 3 test.
Lancet Diabetes Endocrinol. 10, 774u00e2 $ “785 (2022 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Tuttle, K.
R. et al. Physical body body weight and also eGFR during the course of dulaglutide therapy in style 2 diabetic issues and also moderate-to-severe persistent kidney health condition (AWARD-7).
Diabetes mellitus Obes. Metab. 21, 1493u00e2 $ “1497 (2019 ).
Articleu00c2.CASu00c2.Google Scholaru00c2.Heerspink, H. J. L.
et cetera. Effects of tirzepatide versus the hormone insulin glargine on cystatin c-based renal feature: a SURPASS-4 article hoc review. Diabetes mellitus Treatment 46, 1501u00e2 $ “1506 (2023 ).
Articleu00c2.CASu00c2.PubMed Centralu00c2.Google Scholaru00c2.Diabetic Issues Treatment (American Diabetes Affiliation, accessed 1 September 2024) https://diabetesjournals.org/diabetes/issue/73/Supplement_1Li, K. et al. Results of bariatric surgery on renal function in obese individuals: a step-by-step examine as well as meta analysis.
PLoS ONE 11, e0163907 (2016 ). Articleu00c2.PubMed Centralu00c2.Google Scholaru00c2.Bilha, S. C.
et cetera. The effects of bariatric surgery on kidney results: an organized review and meta-analysis. Obes.
Surg. 28, 3815u00e2 $ “3833 (2018 ). Articleu00c2.Google Scholaru00c2.Clerte, M.
et al. The gauged glomerular filtering rate (mGFR) before as well as 6 months after bariatric surgery: a captain study. Nephrol.
Ther. 13, 160u00e2 $ “167 (2017 ). Articleu00c2.Google Scholaru00c2.Fawaz, S.
et al. Adiponectin lowers glomerular endothelial glycocalyx disruption and also repairs glomerular barricade feature in a mouse design of kind 2 diabetes mellitus. Diabetes mellitus 73, 964u00e2 $ “976 (2024 ).
Articleu00c2.CASu00c2.Google Scholaru00c2.Sasson, A. N. & Cherney, D.
Z. Kidney hyperfiltration related to diabetes mellitus as well as weight problems in individual condition. World J.
Diabetes Mellitus 3, 1u00e2 $ “6 (2012 ). Articleu00c2.PubMed Centralu00c2.Google Scholaru00c2.Chagnac, A. & Friedman, A.
N. Assessing albuminuria in individuals with being overweight: downfalls of the urinary albumin-creatinine ratio. Renal Med.
6, 100804 (2024 ). Articleu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.Wilding, J. P.
H. et cetera. Once-weekly semaglutide in adults along with over weight or excessive weight.
N. Engl. J.
Med. 384, 989u00e2 $ “1002 (2021 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Levey, A.
S. et al. An even more exact strategy to approximate glomerular filtration amount from cream creatinine: a brand-new prediction equation.
Adjustment of Diet Plan in Renal Condition Study Hall. Ann. Intern.
Med. 130, 461u00e2 $ “470 (1999 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.Stevens, J.
et al. UHPLC-MS/MS procedure for iohexol determination in individual EDTA and lithium-heparin blood, individual urine and in goat- as well as swine EDTA plasma televisions. Bioanalysis 12, 981u00e2 $ “990 (2020 ).
Articleu00c2.CASu00c2.Google.com Scholaru00c2.Tuttle, K. R. et al.
Effectiveness and safety of aldosterone synthase restraint with and also without empagliflozin for severe kidney illness: a randomised, managed, stage 2 test. Lancet 403, 379u00e2 $ “390 (2024 ). Articleu00c2.CASu00c2.Google Scholaru00c2.de Zeeuw, D.
et cetera. Efficiency of a novel inhibitor of vascular adherence protein-1 in minimizing albuminuria in clients along with diabetic renal ailment (ALBUM): a randomised, placebo-controlled, period 2 trial. Lancet Diabetes Mellitus Endocrinol.
6, 925u00e2 $ “933 (2018 ). Articleu00c2.Google Scholaru00c2.Heerspink, H. J.
L. et al. Zibotentan in combination along with dapagliflozin compared to dapagliflozin in people along with constant kidney ailment (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, professional trial.
Lancet 402, 2004u00e2 $ “2017 (2023 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Heerspink, H. J.
L. et al. Effect of avenciguat on albuminuria in people along with CKD: pair of randomized placebo-controlled trials.
J. Am. Soc.
Nephrol. 25, 1227u00e2 $ “1239 (2024 ). Articleu00c2.Google.com Scholaru00c2.Heerspink, H.
J. L. et cetera.
Sparsentan in patients along with IgA nephropathy: a prespecified interim review due to a randomised, double-blind, active-controlled scientific trial. Lancet 401, 1584u00e2 $ “1594 (2023 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.